Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biolife Solutions (NQ: BLFS )

26.02 -0.05 (-0.19%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 381,546
Open 25.86
Bid (Size) 19.00 (1)
Ask (Size) 26.50 (2)
Prev. Close 26.07
Today's Range 25.48 - 26.89
52wk Range 10.40 - 29.92
Shares Outstanding 42,765,994
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
BioLife Solutions's Return On Capital Employed Insights
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers 
Via Benzinga

Performance

YTD
+47.26%
+47.26%
1 Month
+28.62%
+28.62%
3 Month
+35.66%
+35.66%
6 Month
+22.39%
+22.39%
1 Year
-5.38%
-5.38%

More News

Read More
Why Magnite Shares Are Trading Higher By Over 45%? Here Are 69 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
BioLife Solns: Q2 Earnings Insights
Via Benzinga
Earnings Scheduled For February 28, 2022
Via Benzinga
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
Via Benzinga
Earnings Scheduled For November 11, 2021
Via Benzinga
Earnings Outlook For BioLife Solutions
Via Benzinga
Billionaire Israel Englander Is Betting Big on These 5 Stocks
Via InvestorPlace
60 Biggest Movers From Yesterday
Via Benzinga
Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday
Via Benzinga
34 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
BioLife Solutions: Q4 Earnings Insights
Via Benzinga
BioLife Solutions Inc (BLFS) Q3 2021 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022
Via Benzinga
Have $500? This Under-the-Radar Stock Could Make You Richer From the Biotech Boom
Via The Motley Fool
Exposures COVID-19
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Looking Into BioLife Solutions's Return On Capital Employed
Via Benzinga
Notable Biolife Solutions Insider Trades $971 Thousand In Company Stock
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
Why Shares in BioLife Solutions Jumped 24.4% in August
Via The Motley Fool
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
Via Benzinga
Exposures COVID-19 Product Safety
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
Via Benzinga
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Via Benzinga
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.